- Home
- MLYS
as 10-24-2025 3:52pm EST
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | RADNOR |
| Market Cap: | 3.1B | IPO Year: | 2023 |
| Target Price: | $42.60 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.24 - $44.80 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Mineralys Therapeutics Inc. (MLYS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rodman David Malcom | MLYS | Chief Medical Officer | Oct 15 '25 | Sell | $43.01 | 10,369 | $445,982.10 | 71,155 | |
| Congleton Jon | MLYS | Chief Executive Officer | Oct 13 '25 | Sell | $42.83 | 15,100 | $644,326.87 | 832,857 | |
| Levy Adam Scott | MLYS | CFO and Secretary | Oct 13 '25 | Sell | $42.08 | 10,758 | $451,983.56 | 116,865 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Sep 15 '25 | Sell | $36.19 | 11,367 | $409,265.98 | 71,155 | |
| RA CAPITAL MANAGEMENT, L.P. | MLYS | Director | Sep 4 '25 | Buy | $25.50 | 1,176,470 | $29,999,985.00 | 5,456,521 | |
| AKKARAJU SRINIVAS | MLYS | Director | Sep 4 '25 | Buy | $25.50 | 588,235 | $14,999,992.50 | 588,235 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Aug 13 '25 | Sell | $12.93 | 11,365 | $146,986.95 | 71,155 |
Latest Mineralys Therapeutics Inc. News
MLYS Breaking Stock News: Dive into MLYS Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
24/7 Wall St.
9 days ago
Insiders Bet Big on These 3 Fintech and Biotech Stocks
Simply Wall St.
23 days ago
Why Mineralys Therapeutics (MLYS) Is Up 5.1% After Completing Enrollment in EXPLORE-OSA Hypertension Trial
Insider Monkey
a month ago
Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups
Motley Fool
a month ago
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
MT Newswires
4 months ago
Mineralys Phase 2 Trial of Hypertension, Kidney Disease Drug Meets Primary Endpoint; Shares Up Pre-Bell
GlobeNewswire
4 months ago
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
MT Newswires
4 months ago
Jefferies Initiates Coverage on Mineralys Therapeutics With Hold Rating, $15 Price Target
Compare MLYS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MLYS Mineralys Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.